Centessa Pharmaceuticals Advances OX2R Agonist Pipeline

Centessa Pharmaceuticals Plc ( (CNTA) ) has released its Q1 earnings. Here is a breakdown of the information Centessa Pharmaceuticals Plc presented to its investors.

Centessa Pharmaceuticals Plc is a clinical-stage pharmaceutical company focused on developing transformational medicines, particularly pioneering therapies within the orexin receptor 2 (OX2R) agonist program for various neurological disorders. In its first quarter of 2025, Centessa Pharmaceuticals reported significant advancements in its OX2R agonist pipeline, with key data readouts expected this year. The company is making strides with its ORX750, ORX142, and ORX489 programs, targeting sleep-wake disorders and other neurological conditions. Financially, Centessa reported a net loss of $26.1 million for the first quarter of 2025, a reduction from the $38.0 million loss in the same period of 2024, while its cash reserves are expected to fund operations into mid-2027. Looking ahead, Centessa remains optimistic about its pipeline’s potential, with multiple data readouts anticipated to further establish its position in the OX2R agonist class.